Radiolabeled antibodies for cancer imaging and therapy.

[1]  S. Fanti,et al.  Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  D. Huglo,et al.  High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Beltran,et al.  Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancer , 2010, Cancer.

[4]  F. Kraeber-Bodéré,et al.  Les anticorps radiomarqués pour le traitement des cancers , 2009 .

[5]  Ronald Boellaard,et al.  Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients , 2009, Journal of Nuclear Medicine.

[6]  K. Imrie,et al.  131I–Tositumomab in lymphoma , 2009, Current oncology.

[7]  J. Chatal,et al.  Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors. , 2009, Journal of cancer research and therapeutics.

[8]  L. Jacobsson,et al.  Intraperitoneal α-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab′)2—A Phase I Study , 2009, Journal of Nuclear Medicine.

[9]  A. Hagenbeek,et al.  Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G. Sgouros.  Alpha-particles for targeted therapy. , 2008, Advanced drug delivery reviews.

[11]  Shuang Liu.  Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. , 2008, Advanced drug delivery reviews.

[12]  T. Carlier,et al.  ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicine , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  W. Mcbride,et al.  Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting , 2007, Journal of Nuclear Medicine.

[14]  D. Bigner,et al.  Targeted α-Particle Radiotherapy with 211At-labeled Monoclonal Antibodies , 2007 .

[15]  M. Schwaiger,et al.  213Bi‐radioimmunotherapy defeats early‐stage disseminated gastric cancer in nude mice , 2007, Cancer science.

[16]  J. Humm,et al.  Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. , 2007, The Lancet. Oncology.

[17]  S. Batra,et al.  Optimization of Radioimmunotherapy of Solid Tumors: Biological Impediments and Their Modulation , 2007, Clinical Cancer Research.

[18]  D. Goldenberg,et al.  Update of Carcinoembryonic Antigen Radioimmunotherapy with 131I-Labetuzumab After Salvage Resection of Colorectal Liver Metastases: Comparison of Outcome to a Contemporaneous Control Group , 2007, Annals of Surgical Oncology.

[19]  E. Krenning,et al.  Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate. , 2006, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[20]  D. Goldenberg.  Epratuzumab in the therapy of oncological and immunological diseases , 2006, Expert review of anticancer therapy.

[21]  V. Rohmer,et al.  Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Chatal,et al.  Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Kraeber-Bodéré,et al.  Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. , 2005, The Journal of clinical endocrinology and metabolism.

[24]  J. Jurcic.  Immunotherapy for acute myeloid leukemia , 2005, Current oncology reports.

[25]  J. Teillaud.  Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges , 2005, Expert opinion on biological therapy.

[26]  S. Fosså,et al.  First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases , 2005, Clinical Cancer Research.

[27]  L. Gordon,et al.  Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. , 2004, Clinical lymphoma.

[28]  A. Alavi,et al.  Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  N. Bander,et al.  Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. , 2003, Seminars in oncology.

[30]  B. Cheson.  Radioimmunotherapy of non-Hodgkin lymphomas. , 2003, Blood.

[31]  Gary L Griffiths,et al.  A universal pretargeting system for cancer detection and therapy using bispecific antibody. , 2003, Cancer research.

[32]  L. Gordon,et al.  Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  L. Gordon,et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  T. Waldmann,et al.  Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac. , 2001, Nuclear medicine and biology.

[35]  P. Ell,et al.  Clinical role of positron emission tomography in oncology. , 2001, The Lancet. Oncology.

[36]  R. Jain.  Delivery of molecular and cellular medicine to solid tumors. , 2001, Advanced drug delivery reviews.

[37]  J. Leonard,et al.  Immunotherapy of Non-Hodgkin's lymphomas. , 2001, Hematology. American Society of Hematology. Education Program.

[38]  S. A. Bush,et al.  A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. , 2000, Blood.

[39]  M. Kaminski,et al.  Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. , 2000, Blood.

[40]  Daniel H. S. Silverman,et al.  Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma , 2000, European Journal of Nuclear Medicine.

[41]  G. Griffiths,et al.  90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies. , 1998, Bioconjugate chemistry.

[42]  D Huglo,et al.  Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  R. Jain,et al.  Delivery of molecular and cellular medicine to solid tumors. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[44]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[45]  M. Kaminski,et al.  Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. , 1992, Cancer research.

[46]  M. Brechbiel,et al.  Backbone-substituted DTPA ligands for 90Y radioimmunotherapy. , 1991, Bioconjugate chemistry.

[47]  E. Gautherot,et al.  Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. , 1990, Cancer research.

[48]  G. Denardo,et al.  Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  H. Stein,et al.  Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells , 1987 .

[50]  S. Srivastava.  Investigators review potential of antibodies in cancer detection and therapy. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[51]  H. Strauss,et al.  Differences in experimental tumor localization of dual-labeled monoclonal antibody. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[52]  R. Reba,et al.  Radiolabeling of antibodies. , 1980, Cancer research.

[53]  D. Solter,et al.  Tumor location detected with radioactively labeled monoclonal antibody and external scintigraphy. , 1979, Science.

[54]  M. Herlyn,et al.  Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[55]  M. Herlyn,et al.  Study of antibodies against human melanoma produced by somatic cell hybrids. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[56]  J R van Nagell,et al.  Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. , 1978, The New England journal of medicine.

[57]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[58]  W. Hunter,et al.  The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. , 1973, The Biochemical journal.

[59]  H. Anger.  SCINTILLATION CAMERA WITH MULTICHANNEL COLLIMATORS. , 1964, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[60]  F. Greenwood,et al.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. , 1963, The Biochemical journal.

[61]  F. Greenwood,et al.  Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity , 1962, Nature.